Intuitive Surgical reported adjusted earnings per share of $2.53 for the fourth quarter of 2025, beating the analyst consensus of $2.26 by 12%. Revenue rose 19% year-over-year to $2.87 billion, surpassing the $2.75 billion target. Instrument and accessory sales climbed 17% to $1.66 billion, while systems revenue increased from $655 million to $786 million. The company placed 532 da Vinci systems during the quarter, up from 493 a year earlier, expanding its installed base to 11,106 units, a 12% increase over Q4 2024. Ion procedures surged 44%, further supporting the revenue beat and demonstrating continued end-user adoption of robotic platforms.

In Japan, procedure growth remained below expectations as the Ministry of Health, Labor, and Welfare’s new reimbursement guidelines for additional robotic procedures face implementation delays until June 2026. In China, provincial tenders increasingly favor domestic suppliers offering lower pricing. Management highlighted that the number of local robotic surgical system vendors has doubled in recent quarters, eroding Intuitive’s pricing advantage and pressuring margins. These developments contributed to weaker-than-forecast procedure growth in the region and underscore a heightened need for strategic pricing and market-development initiatives.

Ion system placements declined by 39% year-over-year, with only 42 units installed in Q4 2025 versus 69 placements in the same period of the prior year. Management attributed this drop to U.S. customers prioritizing higher utilization rates, which rose 11% year-over-year, over fleet expansion. While utilization gains support recurring revenue from instruments and accessories, the slowdown in new system deployments highlights a potential saturation point in early adopter markets and may signal longer sales cycles for emerging technologies.

Intuitive Surgical forecasts worldwide da Vinci procedure growth of 13% to 15% for 2026, down from the 18% expansion achieved in 2025. The moderation reflects capital constraints in parts of Europe and potential headwinds from U.S. healthcare policy changes affecting premium subsidies and Medicaid funding. Despite the tempered outlook, a November 2025 Annals of Surgery study spanning 20 years found that robotic-assisted patients were 50% less likely to require subsequent open surgery compared to those undergoing laparoscopic procedures. Management views these clinical outcomes as a catalyst for broader procedure adoption across the estimated 20 million annual soft tissue surgeries worldwide.